Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 2, 1999, Pages 110-115

  Busse, W W ^a   McGill, K A ^a   Horwitz, R J ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Asthma; Bronchial obstruction; Chronic obstructive pulmonary disease; Leukotrienes

Indexed keywords

ANTIHISTAMINIC AGENT; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; PRANLUKAST; ZAFIRLUKAST;

ASTHMA; BRONCHODILATATION; BRONCHUS MUSCLE; CELL SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; EOSINOPHIL; HUMAN; MAST CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; LIPOXYGENASE INHIBITORS; LUNG DISEASES, OBSTRUCTIVE;

EID: 0033011604     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157:1363-71.
2. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171-6.
3. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-55.
4. 4, and histamine in normal human subjects. Thorax 1984; 39:500-4.
5. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 1991; 144:1053-7.
6. Israel E, Fischer AR, Rosenberg MA et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447-51.
7. Hui KP, Taylor IK, Taylor GW et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184-9.
8. Coleman RA, Eglen RM, Jones RL et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prost Throm Leuko Res 1995; 23:283-5.
9. Labat C, Ortiz JL, Norel X et al. A second cysteinyl leukotriene receptor in the lung. J Pharmacol Exp Therap 1992; 263:800-5.
10. Aalbers R, Kauffman HF, Vrugt B et al. Bronchial lavage and bronchoalveolar lavage in allergen-induced single early and dual asthmatic responders. Am Rev Respir Dis 1993; 147:76-81.
11. Taylor I, O'Shaughnessy K, Fuller R, Dollery C. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-4.
12. Kane GC, Pollice M, Kim CJ et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996; 97:646-54.
13. Hamilton A, Faiferman I, Stokes D, Watson RM, O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early-and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J All Clin Immunol 1998; 102:177-83.
14. Roquet A, Dahlén B, Kumlin M et al. Combined antagonism of leukotrienes and histamine products produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155:1856-63.
15. Calhoun WJ, Lavins BJ, Minkwitz MC et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am J Respir Care 1998; 157:1381-9.
16. Finnerty J, Wood-Baker R, Thomson H, Holgate S. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992; 145:746-9.
17. 4-receptor antagonist. N Engl J Med 1990; 323:1736-9.
18. Leff JA, Busse WW, Pearlman D et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-52.
19. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153:931-5.
20. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E Jr, Reed CE et al. (eds). Allergy, Principles and Practice. St Louis: CV Mosby 1993:1747-65.
21. Dahlén B, Nizankowska E, Szceklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspiring-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187-94.
22. 4 antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1995; 150:618-23.
23. Reiss TF, Chervinsky P, Edwards T et al. Shingo, and the Montelukast Study Group. Montelukast (MK-0476), a cysLT, receptor antagonist, improves asthma outcomes over a 3-month treatment period. Am J Respir Crit Care Med 1997; 1555:A662(Abstract).
24. Leff JA, Israel E, Noonan MJ et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids in asthmatic patients while maintaining clinical stability. Am J Respir Crit Care Med 1997; 155:A976 (abstract).
25. Israel E, Rubin P, Kemp JP et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059-66.
26. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 1996; 275:931-6.
27. Wenzel SE, Trudeau JB, Kaminsky DA et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152:897-905.